NRx Pharmaceuticals received expanded Fast Track Designation from the FDA for NRX-100, addressing a market of 13 million Americans with depression. They also filed for a National Priority Voucher for intravenous ketamine. Additionally, the company submitted a patent application and a Citizen’s Petition to remove a toxic preservative from ketamine products.

HOPE Therapeutics finalized acquisitions and secured debt financing for clinic acquisitions. They also formed strategic partnerships and received regulatory clearance for acquisitions. The company is focused on building an interventional psychiatry clinic network to treat depression and related disorders.

NRx Pharmaceuticals announced a $6.5 million investment from a consortium of biotechnology investors. The investment is subject to a one-year lockup and aims to support the company’s growth and development. The company also conducted a toxicology assessment and filed for patents and a New Drug Application for their products.

NRx Pharmaceuticals provided updates on their drug development efforts for NRX-100 and NRX-101. They aim to enter the ketamine market and treat suicidal depression with their innovative formulations. The company also received Fast Track Designation and filed for a National Priority Voucher to expedite approvals.

NRx Pharmaceuticals reported a net loss of $17.6 million for the quarter ended June 30, 2025. They believe their current cash position will support operations into 2026 and help them reach expected regulatory milestones. The company is focused on advancing their drug development programs and expanding their clinic network under HOPE Therapeutics.

Read more at GlobeNewswire: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second